MPower Partners Fund II (hereinafter, MPower), a global venture capital fund, has invested in HistoSonics, Inc. (hereinafter, HistoSonics), a US-based medical device company developing a non-invasive cancer treatment platform using focused ultrasound. MPower participated in this round alongside other strategic investors, including Yosemite, which has a mission to "make cancer a non-lethal disease for life." In cancer treatment, patients have historically faced difficult choices between "treatment efficacy" and "burden on the body." Traditional therapies such as surgery, radiation, and ablation damage healthy tissues, requiring long recovery periods and diminishing patients' quality of life. HistoSonics is challenging this with an approach that overturns conventional cancer treatment by destroying only tumors without the need for scalpels, radiation, or heat. The core of HistoSonics' platform, the Edison® histotripsy system, delivers precisely focused ultrasound energy via a robotic arm to mechanically destroy and liquefy target tumors at the cellular level. In 2023, it received FDA De Novo clearance as a medical device for the non-invasive destruction of liver tumors. Currently, Edison is the world's only histotripsy system approved for clinical use. In recent years, evidence suggesting that the mechanical destruction of tumor tissue may activate the body's immune response has been accumulating, leading to expectations for new developments in treatment. HistoSonics is experiencing rapid growth in the US market, with Edison® being steadily adopted by major university hospitals and medical institutions nationwide. Most recently, the company submitted an FDA De Novo application for the treatment of kidney tumors and is accumulating promising clinical data for pancreatic tumors. The ultimate goal is to realize a platform that can address solid tumors throughout the body. The number of people who have difficulty undergoing surgery due to tumors, or who seek gentler treat